S. 4510 · 118th Congress · Health

Kidney PATIENT Act of 2024

Died in committee407 words Introduced Jun 11, 2024 · Latest action Jun 11, 2024

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedJun 11, 2024 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

Full text

No CRS summary yet · 407 words

S. 4510 · Introduced in Senate · Jun 11, 2024

SECTION 1. SHORT TITLE.

This Act may be cited as the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024 or the Kidney PATIENT Act of 2024 .

SEC. 2. PROHIBITION OF IMPLEMENTATION OF ORAL-ONLY POLICY FOR CERTAIN DRUGS UNDER MEDICARE ESRD PROSPECTIVE PAYMENT SYSTEM.

(a) In general. Section 632(b) of the American Taxpayer Relief Act of 2012 ( 42 U.S.C. 1395rr note) is amended— (1) in the heading, by striking Two-year delay and inserting Delay ; and (2) in the first sentence of paragraph (1), by striking may not implement and all that follows through January 1, 2025. and inserting may not implement the policy under section 413.174(f)(6) of title 42, Code of Federal Regulations (relating to oral-only ESRD-related drugs in the ESRD prospective payment system) with respect to such drugs indicated for the reduction, management, or control of the serum phosphate of an individual before January 1, 2027. .

(b) Study. Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services shall submit to Congress and make available on the public website of the Centers for Medicare & Medicaid Services a report containing data from 2022 through 2024 on— (1) the number of individuals entitled to benefits under part A of title XVIII of the Social Security Act ( 42 U.S.C. 1395c et seq. ) or enrolled under part B of such title ( 42 U.S.C. 1395j et seq. ) with end-stage renal disease who are enrolled under a prescription drug plan under part D of such title ( 42 U.S.C. 1395w–101 et seq. ) or under an MA–PD plan under part C of such title ( 42 U.S.C. 1395w–21 et seq. ), along with a specification of any gaps in coverage under such prescription drug plans or MA–PD plans; (2) the amount of expenditures under such part D attributable to oral-only drugs related to the treatment of end-stage renal disease and the amount of cost sharing incurred by such individuals for such drugs; (3) such individuals’ adherence to prescriptions for such drugs, including as measured by serum phosphate levels, reported through the end-stage renal disease quality reporting system; (4) adverse events of such individuals related to hyperphosphatemia and estimated costs attributable to such adverse events under such title; and (5) any recommended strategies or standards of practice to increase adherence to prescribed phosphate binders or lowering agents or other strategies to reduce costs to such individuals and expenditures under such program for such agents.

Shown here because the text is under 500 words. Open on Congress.gov

Who lobbies on it

4 organizations · 21 filings · Q2 2024–Q4 2024

These 4 organizations’ PACs gave $27.5K to 4 of the 9 members sponsoring or cosponsoring S. 4510 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the Senate → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Fresenius Medical Care North America 3 of 3 quarters
    “Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 10545, American Relief Act…”

    $6.5M lobbying spend in 2024, all issuesQ4 2024 filing

  2. Davita Inc. 3 of 3 quarters
    “Issues related to the Medicare Secondary Payer Act, including HR 6860 and S. 5018, Restore Protections for Dialysis Patients Act; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act, H.R. 5074/S. 4510; issues related to home dialysis.”

    $4.2M lobbying spend in 2024, all issuesQ4 2024 filing

  3. Ardelyx, Inc. 3 of 3 quarters
    “Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act”

    $2.5M lobbying spend in 2024, all issuesQ4 2024 filing

1 more organization, every filingPROUpgrade

Organizations that named S. 4510 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Jun 11, 2024Read twice and referred to the Committee on Finance.
  2. Jun 11, 2024Introduced in Senate